Viking Therapeutics launches phase 3 trials for oral obesity drug

Viking Therapeutics initiated the SUNRISE Phase 3 program for oral VK2735, with two 560-participant trials testing daily doses of 27.5 mg, 35 mg, and 55 mg against placebo over 68 weeks. The primary endpoint is percent change in body weight; the program follows Phase 2 results showing up to 12.2% mean weight reduction after 13 weeks. Viking is also conducting two fully enrolled Phase 3 trials of weekly subcutaneous VK2735, with approximately 4,500 and 1,000 participants.

Analysis

The investable signal is operational de-risking for Viking’s oral program, not proof of a differentiated product: Phase 2 data are company-reported, short-duration results, while the Phase 3 primary readout is 68 weeks away. The smaller oral trials also leave more uncertainty around dose selection, tolerability, discontinuation and performance in type 2 diabetes than the headline weight-loss figures alone suggest. The parallel injectable program may provide nearer-term evidence, but oral and injectable results should not be treated as interchangeable.

The strategic prize is convenience and broader treatment access, but Viking must compete against established obesity-drug developers with greater commercial scale. A successful oral profile could improve Viking’s licensing or partnership leverage; merely matching efficacy without competitive tolerability, adherence or access would not establish a durable advantage. Near term, the program start supports sentiment, while 1–3 month catalysts are likely to depend on trial execution and any additional clinical disclosures. Structural value depends on Phase 3 results and eventual regulatory/commercial execution over a multi-year horizon.

The contrarian point: initiating large trials is not equivalent to reducing the core efficacy risk, and a long data runway makes VKTX vulnerable to changes in competitor data and obesity-drug expectations. The supplied headline references ASML, but the article body contains no ASML information; no ASML inference is warranted.

Key Decisions for Investors

• VKTX: treat the update as a modest de-risking catalyst, not a basis for extrapolating Phase 2 efficacy into commercial value. Consider a staged, risk-sized long only if valuation and portfolio exposure leave room for a binary clinical drawdown; avoid chasing a sharp headline-driven gap without checking the current price reaction.
• For the next 1–3 months, monitor trial initiation/enrollment cadence, dose selection, safety and discontinuation disclosures, plus readouts from the injectable VANQUISH studies. Verify trial registry updates and subsequent company filings rather than relying solely on press-release efficacy claims.
• Falsification: evidence of material tolerability or adherence problems, delays or changes to the oral Phase 3 program, or injectable results that weaken confidence in VK2735’s efficacy profile. Longer-term thesis requires Phase 3 efficacy and safety competitive with established obesity therapies; trial commencement alone does not meet that bar.
• No ASML trade: its presence in the headline is unsupported by the article body.